Mark Mugerditchian

Dura Pharmaceuticals, Inc. markets and sells prescription products that treat infectious and respiratory diseases. Dura focuses on products and transactions that leverage its sales and marketing organization. Dura also intends, through the use of collaborative relationships, to develop the Spiros® motorized blisterdisk and Spiros® S2 pulmonary drug delivery systems for the local and systemic delivery of a wide range of medications. It is located in San Diego, CA.

Laguna Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. Its lead product, Vanoxerine is a therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. The firm’s product is a potential pharmaceutical option to rapidly terminate atrial fibrillation in both hospital and home settings. The company was founded in 2006 by Arthur M. Brown and Howard C. Dittrich and is headquartered in Cleveland, OH.

Part of Fujisawa Healthcare, Inc., Fujisawa USA, Inc. is a company based in Bannockburn, IL.

Key Pharmaceuticals, Inc. operates as a subsidiary of Schering-Plough which is engaged in manufacturing, fabricating or processing drugs in pharmaceutical preparations. The company is located in Newark, NJ

Sequel Pharmaceuticals, Inc. engaged in the development of cardiovascular drug. The company was founded in 2007 and was headquartered in San Diego, CA.

NovaCardia, Inc. develops drugs to treat cardiovascular diseases. The company provides treatment for the patients by developing and commercializing clinical stage drug diseases. It also develops small molecule drugs. the company was founded in November, 2001 by Eckard Weber & Howard C. Dittrich and is headquartered in San Diego, CA.